Altmetric

Mapping the complete glycoproteome of virion-derived HIV-1 gp120 provides insights into broadly neutralizing antibody binding

File Description SizeFormat 
srep32956.pdfPublished version2.36 MBAdobe PDFView/Open
Title: Mapping the complete glycoproteome of virion-derived HIV-1 gp120 provides insights into broadly neutralizing antibody binding
Authors: Panico, M
Bouché, L
Binet, D
O'Connor, MJ
Rahman, D
Pang, PC
Canis, K
North, SJ
Desrosiers, RC
Chertova, E
Keele, BF
Bess, JW
Lifson, JD
Haslam, SM
Dell, A
Morris, HR
Item Type: Journal Article
Abstract: The surface envelope glycoprotein (SU) of Human immunodeficiency virus type 1 (HIV-1), gp120SU plays an essential role in virus binding to target CD4+ T-cells and is a major vaccine target. Gp120 has remarkably high levels of N-linked glycosylation and there is considerable evidence that this “glycan shield” can help protect the virus from antibody-mediated neutralization. In recent years, however, it has become clear that gp120 glycosylation can also be included in the targets of recognition by some of the most potent broadly neutralizing antibodies. Knowing the site-specific glycosylation of gp120 can facilitate the rational design of glycopeptide antigens for HIV vaccine development. While most prior studies have focused on glycan analysis of recombinant forms of gp120, here we report the first systematic glycosylation site analysis of gp120 derived from virions produced by infected T lymphoid cells and show that a single site is exclusively substituted with complex glycans. These results should help guide the design of vaccine immunogens.
Issue Date: 8-Sep-2016
Date of Acceptance: 17-Aug-2016
URI: http://hdl.handle.net/10044/1/40033
DOI: http://dx.doi.org/10.1038/srep32956
ISSN: 2045-2322
Publisher: Nature Publishing Group
Journal / Book Title: Scientific Reports
Volume: 6
Copyright Statement: This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
Sponsor/Funder: Biotechnology and Biological Sciences Research Council (BBSRC)
Wellcome Trust
Funder's Grant Number: BB/K016164/1
102978/Z/13/Z
Publication Status: Published
Open Access location: http://www.nature.com/articles/srep32956
Article Number: 32956
Appears in Collections:Faculty of Natural Sciences



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commons